Amarin Corp Plc (AMRN)

[Whalatane]

Well I figured you must have started early given the over the top valuations you are putting on AMRN .
Fact is
We fight to maintain our market share in the US by matching ( or bettering ) generic pricing ...its a zombie Co here with scripts basically flat lining .
We face opinions like this in the EU ...this is from France

HAS is against reimbursement in other populations of the indication, including patients with severe hypertriglyceridemia (≥ 500 mg/dL) and those with diabetes and at least one other cardiovascular risk factor (primary prevention), due to the uncertainties about the differences in effect observed versus placebo, which could be biased in favor of Vazkepa.

Uncertainties about the differences in effect observed vs placebo ? ...don't tell PD

The 3 mth script numbers following the HEART UK Amarin symposia will tell you if there's any hope in the UK ( England / Wales ) . Those are the numbers to watch IMHO

Kiwi